Editorial

Exercise Training in Pulmonary Hypertension
Implications for the Evaluation of Drug Trials

John H. Newman, MD; Ivan M. Robbins, MD

The response to exercise training reported in this issue of Circulation should change the way we perceive and treat selected patients with pulmonary hypertension (PH) and brings into focus the problem of measuring the effects of drug therapy in this condition.1

In a highly structured 15-week program of daily exercise, patients with PH experienced a mean increase of 96 ± 61 meters in the 6-minute walking test from a baseline of 439 ± 82. The increase in the 6-minute walking distance after exercise training was greater than that achieved with prostacyclin formulations, endothelin receptor antagonists,2 and phosphodiesterase inhibitors. By comparison, the baseline and incremental increases in the 6-minute walking distance in studies of successful drug therapies range from a low of 297 ± 31 meters with epoprostenol3 to 342 ± 51 with sildenafil.4 The study group consisted of 24 patients with idiopathic pulmonary arterial hypertension and 6 patients with chronic thromboembolic PH. Fifteen patients were initially entered into the active exercise program, and 15 control patients crossed over to the exercise program after the first 15 weeks. Although not explicitly stated, it appears that there were no patients with the scleroderma spectrum of disease entered in the study, presumably because of the inability to exercise. Other patients with musculoskeletal limitations were excluded as well. Clearly, the cohort in the present study had a higher baseline physical capacity than patients reported in most drug trials, and this may be partly responsible for the greater increase in 6-minute walk than previously reported.

The exercise program was both comprehensive and intense. Patients were hospitalized for the first 3 weeks and exercised under supervision 7 days a week. The exercise program had 3 components: Patients rode a cycle ergometer to 60% to 80% of maximal heart rate for 10 to 25 minutes, walked for 60 minutes 5 days per week on flat and uphill grades, and performed 30 minutes of low-weight dumbbell lifting 5 days a week. All patients had a physiotherapist in attendance and underwent fitness education. For the remain-

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.

Correspondence to John H. Newman, MD, Elsa S. Hanigan Professor of Pulmonary Medicine, T 1218 Vanderbilt Medical Center North, Nashville, TN 37232-2650. E-mail john.newman@vanderbilt.edu (Circulation. 2006;114:1448-1449.)

© 2006 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org
DOI: 10.1161/CIRCULATIONAHA.106.649079

1448
whether an exercise program gives a durable improvement in cardiopulmonary function over longer periods of time or improves survival. It also might be difficult and dangerous to enroll patients in an exercise regimen before the initiation of drug therapy. However, the response to exercise training highlights a degree of uncertainty that exists in the PH community about how to assign clinical value to variations in the 6-minute walk. This study raises the questions of what level of fitness or training should be expected or documented before a baseline 6-minute walk in patients entered into drug trials and whether concomitant exercise training should accompany drug therapy.

Although the results of the study by Mereles et al are impressive, they cannot be assumed to represent the responses of a larger cohort of patients with PH. Although the group of 30 patients was randomly entered into either the initial or subsequent exercise group, little is said about original recruitment criteria. Presumably, these were highly motivated and otherwise fit individuals willing and able to suspend their normal lives during an experiment of high intensity that obligated patients to remain in the hospital for 3 weeks. This kind of exercise training would be virtually impossible to implement broadly in populations that included primary family wage earners, those with insufficient healthcare coverage, and those living a great distance from the treatment center or with no access to local rehabilitation facilities. A caveat to this study is that it was a program of high intensity in a selected subset of patients. The feasibility of its implementation in a large population of patients with PH is problematic, and therefore its general applicability to all patients with PH is unproven.

In summary, this is an important study that shows that exercise training can have an impact on short-term functioning and well-being in selected patients with PH that is equal to the best current drug therapies. Whether this effect is durable or improves survival is unknown. The study does suggest that fitness training should be considered for all patients with PH at some point in their treatment plan, recognizing that not all patients will be capable or will qualify. Because exercise training has short-term effects on exercise performance that are similar to drug therapies, future studies will need to account for fitness and conditioning.

Acknowledgments
Drs Newman and Robbins are supported by grants NHLBI PO 072058 and GRCC RR095.

Disclosures
None.

References

Key Words: Editorials exercise hypertension, pulmonary
Exercise Training in Pulmonary Hypertension: Implications for the Evaluation of Drug Trials
John H. Newman and Ivan M. Robbins

Circulation. 2006;114:1448-1449
doi: 10.1161/CIRCULATIONAHA.106.649079
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/114/14/1448